Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer

An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

The purpose of this trial is to evaluate the efficacy of TAS-118 plus Oxaliplatin compared with S-1 plus Cisplatin in overall survival in patients with advanced gastric cancer.

Key Inclusion Criteria:

• Patients who are diagnosed as gastric cancer.
• No prior treatment for gastric cancer.
• Negative or unknown for HER2 testing.
• ECOG performance status of 0 or 1.

Key Exclusion Criteria:

• Unmanageable diarrhea.
• Current peripheral sensory neuropathy or paresthesia.
• Pregnant or lactating female.